BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
latest_posts
- 1
A definitive Burger Confrontation: Which One Rules? - 2Honda’s Biggest Flex Isn’t Its Superbikes, It’s Selling 500K Bikes In One Month
- 3Parents who delay baby's first vaccines also likely to skip measles shots
- 4Putin says Russian forces will seize capital of Zaporizhzhya
- 5Chinese mega embassy could bring security advantages, says No 10
- The Best Computer games for Multiplayer Fun
- Geminid meteors streak under green sky | Space photo of the day for Dec. 19, 2025
- Make your choice for the PS5 game that you love playing with companions!
- Vote In favor of Your Number one Savvy Beds
- Audits of Espresso Types: Which Mix Is for You?
- Want to be better about saving money in 2026? Try these money-saving tips for having a ‘low-buy’ January and beyond
- Rick Steves Doesn't Want You Overlooking This Food Spot While In France
- Support Your Wellness: 20-Minute Home Exercises That Work
- 4 buzzy new TV shows to watch — plus the return of 'The Comeback,' 'Jury Duty' and more
